Study of SGLT2i in adults with congenital heart disease
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial is a registry that follows adults with congenital heart disease who have started taking an SGLT2 inhibitor medication. The goal is to learn how well this treatment works for this group of patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a heart defect you were born with (congenital heart disease).
- You are 18 years of age or older.
- You have started taking a type of medication called an SGLT2 inhibitor (like empagliflozin or dapagliflozin).
- You agree to allow the study to collect your medical information.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a type of diabetes medicine (SGLT2 inhibitor) to see if it can help people who had surgery for tetralogy of Fallot feel better and have stronger heart and lung function. It may be a good fit if you are an adult with repaired tetralogy of Fallot and do not have certain other health problems.
This study tests whether a type of diabetes medication called an SGLT2 inhibitor can improve the structure and function of the heart's left atrium in people with type 2 diabetes. It may help prevent heart problems in the future.
This study tests whether a medicine called an SGLT2 inhibitor (a type of diabetes drug also used for heart failure) affects the heart and blood vessels in people with kidney failure who are on dialysis. It will help doctors understand if this medicine is safe and helpful for dialysis patients.
This trial is testing a medication called SGLT2i (a type of diabetes drug that also helps the heart and kidneys) in people who have received a heart transplant. It aims to see if this drug can improve health after transplant.
This trial studies whether starting an SGLT-2 inhibitor around the time of a heart attack can reduce heart damage size and improve how the heart heals. It focuses on people with a high risk of developing heart failure and who are getting a procedure to open blocked heart arteries.
This trial tests if an SGLT2i medication can help protect heart function in people with Duchenne muscular dystrophy (DMD). The drug is already approved for other conditions, and researchers want to see if it can slow or prevent heart muscle damage.
Hear when a new Adult Congenital Heart Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.